Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Teneligliptin, a New DPP-IV Inhibitor, in Healthy Volunteers

被引：0
|
作者：
Kumagai, Yuji
Fujita, Tomoe
Kawaguchi, Atsuhiro
Hayashi, Yoshiharu
Kondou, Kazuoki
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A193 / A193
页数：1
相关论文
共 50 条
  • [1] The pharmacokinetics and pharmacodynamics of PF-00734200, a DPP-IV inhibitor, in healthy Japanese subjects
    Muto, Chieko
    Dai, Haiqing
    Teeter, John G.
    Johnson, Susan
    Cropp, Anne B.
    Chiba, Koji
    Suwa, Toshio
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (07) : 505 - 509
  • [2] Pharmacokinetics and Pharmacodynamics of PF-734200, a DPP-IV Inhibitor, in Healthy Japanese Subjects
    Dai, Haiqing
    Johnson, Susan L.
    Muto, Chieko
    Banerjee, Subhashis
    Yachi, Yasunori
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    [J]. DIABETES, 2009, 58 : A534 - A534
  • [3] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Susanne Johansson
    David P. Rosenbaum
    Mikael Knutsson
    Maria Leonsson-Zachrisson
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 407 - 416
  • [4] Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
    Al-Karagholi, Mohammad Al-Mandi
    Hansen, Jakob Moller
    Abou-Kassem, Dalia
    Hansted, Anna Koldbro
    Ubhayasekera, Kumari
    Bergquist, Jonas
    Vecsei, Laszlo
    Jansen-Olesen, Inger
    Ashina, Messoud
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [5] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Johansson, Susanne
    Rosenbaum, David P.
    Knutsson, Mikael
    Leonsson-Zachrisson, Maria
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 407 - 416
  • [6] Safety, tolerability, pharmacokinetics and pharmacodynarnics of SK-0403, a novel DPP-IV inhibitor, in healthy Japanese subjects
    Sunami, Yukiko
    Yoshioka, Naoya
    Hayashi, Ichiro
    Ishida, Tsutomu
    Ishida, Tomu
    [J]. DIABETES, 2007, 56 : A128 - A129
  • [7] The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
    Shi, Jack G.
    Chen, Xuejun
    Lee, Fiona
    Emm, Thomas
    Scherle, Peggy A.
    Lo, Yvonne
    Punwani, Naresh
    Williams, William V.
    Yeleswaram, Swamy
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1354 - 1361
  • [8] Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trial
    Hou, Jie
    Guan, Wei Jie
    Li, Fang Qiong
    Zeng, Wei Fang
    Liu, Han Mo
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
    Alain Munafo
    Anthony Priestley
    Ivan Nestorov
    Jennifer Visich
    Mark Rogge
    [J]. European Journal of Clinical Pharmacology, 2007, 63 : 647 - 656
  • [10] Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
    Munafo, Alain
    Priestley, Anthony
    Nestorov, Ivan
    Visich, Jennifer
    Rogge, Mark
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (07) : 647 - 656
12345